BR0112515A - Complexo protéico utilizado como veìculo para medicamentos oralmente administráveis - Google Patents

Complexo protéico utilizado como veìculo para medicamentos oralmente administráveis

Info

Publication number
BR0112515A
BR0112515A BR0112515-0A BR0112515A BR0112515A BR 0112515 A BR0112515 A BR 0112515A BR 0112515 A BR0112515 A BR 0112515A BR 0112515 A BR0112515 A BR 0112515A
Authority
BR
Brazil
Prior art keywords
protein complex
vehicle
orally administered
complex used
administered medicines
Prior art date
Application number
BR0112515-0A
Other languages
English (en)
Original Assignee
Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh filed Critical Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh
Publication of BR0112515A publication Critical patent/BR0112515A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

"COMPLEXO PROTéICO UTILIZADO COMO VEìCULO PARA MEDICAMENTOS ORALMENTE ADMINISTRáVEIS". A presente invenção refere-se a um complexo protéico que compreende uma ou várias proteínas do complexo ou derivados de Clostridium botulinum tipo A, B, C~ 1~, C~ 2~, D, E, F ou G, e um polipeptídeo ou fármaco de baixo peso molecular, selecionados.
BR0112515-0A 2000-07-19 2001-07-19 Complexo protéico utilizado como veìculo para medicamentos oralmente administráveis BR0112515A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10035155 2000-07-19
DE10035156A DE10035156A1 (de) 2000-07-19 2000-07-19 Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel
PCT/DE2001/002816 WO2002005844A2 (de) 2000-07-19 2001-07-19 Proteinkomplex als vehikel für oral verfügbare arzneimittel

Publications (1)

Publication Number Publication Date
BR0112515A true BR0112515A (pt) 2003-07-01

Family

ID=26006444

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112515-0A BR0112515A (pt) 2000-07-19 2001-07-19 Complexo protéico utilizado como veìculo para medicamentos oralmente administráveis

Country Status (18)

Country Link
US (1) US20040028703A1 (pt)
EP (1) EP1303535A2 (pt)
JP (1) JP2004503600A (pt)
KR (1) KR100822006B1 (pt)
CN (1) CN100497379C (pt)
AU (2) AU8568801A (pt)
BR (1) BR0112515A (pt)
CA (1) CA2415712A1 (pt)
CU (1) CU23381A3 (pt)
CZ (1) CZ2003169A3 (pt)
DE (2) DE10035156A1 (pt)
HU (1) HUP0301644A3 (pt)
IL (1) IL153539A0 (pt)
MX (1) MXPA03000566A (pt)
NO (1) NO20030231L (pt)
PL (1) PL364993A1 (pt)
RU (1) RU2002134755A (pt)
WO (1) WO2002005844A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
JP2003009897A (ja) * 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
JP2007070225A (ja) * 2003-07-25 2007-03-22 Yukako Fujinaga クロストリジウム属菌由来成分を含む医薬製剤
DE102004035606A1 (de) * 2004-07-22 2006-03-30 Biotecon Therapeutics Gmbh Carrier für Arzneimittel zur Gewinnung der oralen Bioverfügbarkeit
EP1778652A2 (en) * 2004-08-20 2007-05-02 EntreMed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
JP2009081997A (ja) * 2007-09-27 2009-04-23 Chemo Sero Therapeut Res Inst ボツリヌス毒素成分ｈａを核酸の細胞内導入キャリアーとして利用する方法
WO2009131435A1 (en) * 2008-04-23 2009-10-29 Erasmus University Medical Center Rotterdam Linker containing bungarotoxin and a binding peptide
WO2010096134A1 (en) 2008-12-04 2010-08-26 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
US20130085267A1 (en) * 2009-12-18 2013-04-04 Allergan, Inc. Stabilization of Therapeutic Agents to Facilitate Administration
KR101134146B1 (ko) * 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11096993B2 (en) 2016-12-08 2021-08-24 Gary E. Borodic Method of treating macular degeneration using botulinum toxin-based pharmaceuticals
US11123411B2 (en) * 2016-12-08 2021-09-21 Gary E. Borodic Method of treating macular degeneration using botulinum toxin-based pharmaceuticals
US20210121542A1 (en) * 2019-10-28 2021-04-29 Prime Bio, Inc. Composition for delivery of protein therapeutics through oral, sublingual and buccal route

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ242065A (en) * 1991-03-26 1996-06-25 Csl Ltd Delayed release implant having a degradable or rupturable polymeric coating
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
WO1994000481A1 (en) * 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
PT692974E (pt) * 1993-03-29 2003-09-30 Pfizer Vacinas clostridiais com multiplos componentes usando adjuvantes de saponina
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
CA2164626C (en) * 1993-06-10 2004-11-23 K. Roger Aoki Multiple botulinum toxins for treating neuromuscular disorders and conditions
US6203794B1 (en) * 1994-05-31 2001-03-20 Allergan Sales, Inc. Modification of clostridial toxins for use as transport proteins
US6004583A (en) * 1995-03-22 1999-12-21 Orex Pharmaceutical Development Corp. Protein-containing polymer composition for oral administration
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US6699966B1 (en) * 1996-07-08 2004-03-02 University Of Massachusetts Proteins within the type E botulinum neurotoxin complex
DE19735105A1 (de) * 1997-08-13 1999-03-04 Univ Albert Ludwigs Freiburg Transportsystem zur Einbringung von Proteinen in Zielzellen mit Hilfe eines Fusionsproteins, Nucleinsäurekonstrukte kodierend für die Komponenten des Transportsystems und Arzneimittel, die Komponenten des Transportsystems umfassen
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
GB9721189D0 (en) * 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
JP2002501033A (ja) * 1998-01-26 2002-01-15 ユニバーシティー オブ マサチューセッツ Ａ型ボツリヌス菌の生物学的活性赤血球凝集素とその使用法
US5955368A (en) * 1998-04-06 1999-09-21 Wisconsin Alumni Research Foundation Expression system for clostridium species
DE19856897A1 (de) * 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum zur Unterdrückung von Schnarchgeräuschen
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
NZ520201A (en) * 2000-02-08 2004-04-30 Allergan Inc Botulinum toxin pharmaceutical compositions comprising a polysaccharide
JP2003009897A (ja) * 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
US20040013687A1 (en) * 2002-05-31 2004-01-22 Thomas Jefferson University Compositions and methods for transepithelial molecular transport
US20050169942A1 (en) * 2003-10-07 2005-08-04 Allergan, Inc. Novel DNA sequences of the botulinum neurotoxin complex of Clostridium botulinum type A-Hall (Allergan) strain for production of therapeutics
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
AU2006227816B2 (en) * 2005-03-15 2012-04-05 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
FR2896693B1 (fr) * 2006-01-27 2008-03-14 Sod Conseils Rech Applic Composition comprenant plusieurs toxines botuliques

Also Published As

Publication number Publication date
AU2001285688B2 (en) 2005-09-08
RU2002134755A (ru) 2004-07-10
CU23381A3 (es) 2009-06-25
DE10192679D2 (de) 2003-06-18
WO2002005844A3 (de) 2002-06-27
KR20030045013A (ko) 2003-06-09
EP1303535A2 (de) 2003-04-23
IL153539A0 (en) 2003-07-06
HUP0301644A3 (en) 2010-01-28
NO20030231L (no) 2003-03-18
JP2004503600A (ja) 2004-02-05
HUP0301644A2 (hu) 2003-08-28
NO20030231D0 (no) 2003-01-17
CN1443196A (zh) 2003-09-17
KR100822006B1 (ko) 2008-04-15
WO2002005844A8 (de) 2002-02-14
MXPA03000566A (es) 2004-12-13
WO2002005844A2 (de) 2002-01-24
US20040028703A1 (en) 2004-02-12
AU8568801A (en) 2002-01-30
CN100497379C (zh) 2009-06-10
CZ2003169A3 (cs) 2004-02-18
PL364993A1 (en) 2004-12-27
DE10035156A1 (de) 2002-02-07
CA2415712A1 (en) 2003-01-10

Similar Documents

Publication Publication Date Title
BR0112515A (pt) Complexo protéico utilizado como veìculo para medicamentos oralmente administráveis
BR9907647A (pt) Composições contendo composto orgânicos
BRPI0607549A2 (pt) sistemas de distribuição farmacêutica para fármacos hidrófobos e composições compreendendo os mesmos
BR0114927A (pt) Composição de gel farmacêutica substancialmente não aquosa para aplicação na pele, e, uso da composição
DE60315145D1 (de) Hydrophiles polymerderivat mit y-verzweigung und herstellungsverfahren dafür; obige verbindung enthaltender medizinischer verbundwerkstoff
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
DK0910647T3 (da) Human DNase i hyperaktive varianter
BRPI9605663B8 (pt) Bis (resorcinil) triazinas.
BRPI0411172A (pt) peptìdeo, dìmero de peptìdeo, seu uso e composição farmacêutica
HUP9900346A2 (hu) Avermektineket és depszipeptideket tartalmazó endoparazita ellenes hatású gyógyászati készítmények
BR0113822A (pt) Vacina
BRPI0407293A (pt) Resposta duradoura da célula t
BRPI0510004A (pt) artigo de manufatura, métodos para administrar uma composição terapêutica a um epitélio de um indivìduo, para tratar uma condição mediada por micróbio de um epitélio de um indivìduo, para melhorar um sintoma de uma condição e para prevenir uma condição, e, uso de composto tipo peg pma
DE69808297T2 (de) Oral anzuwendende arzneizubereitungen enthaltend eine benzhydrylpiperazine und eine zyklodextrin
FR2852957B1 (fr) Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
ATE345775T1 (de) Zusammensetzungen zur verabreichung von arzneimittelkombinationen
BR0014826A (pt) Imidazo-3-il-aminas bicìclicas, procedimento de sua preparação e medicamentos que as contêm
ES2168457T3 (es) Composiciones farmaceuticas que comprenden una superoxido dismutasa.
BR0012919A (pt) Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv
PT1079849E (pt) Utilizacao de proteinas hmg para a preparacao de medicamentos com actividade citotoxica
BR0107958A (pt) Composição farmacêutica contendo pemetrexado juntamente com l-cisteìna monotrioglicerol ou ácido tioglicólico
BR0213291A (pt) Composição e método para tratamento de diabetes
BR0215124A (pt) Compostos e seus usos, composições farmacêutica e cosmética e uso cosmético de uma composição cosmética
DK0707473T3 (da) Orale farmaceutiske præparater omfattende et protein eller et peptid, et antistof og polymerkugler
BR0312318A (pt) Compostos, uso de um ou mais compostos, composição farmacêutica, composição cosmética e usos cosméticos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.